Introduction

On May 19, 2023, the FDA granted accelerated approval to Epyridomab for adult patients with relapsed refractory DLBCL. This regulatory decision was backed by findings from the Phase 1-2 Epcor-NHL-1 trial. In our exclusive interview, Dr. Tysell Phillips discussed the significance of this approval and key efficacy and safety findings from Epcor- NHL-1. We also discuss the potential future of vice-specific antibodies in this setting.